Talk Bio

The FDA issued three Commissioner's National Priority Vouchers (CNPVs) to Compass Pathways, Transcend Therapeutics (being acquired by Otsuka), and Usona Institute for their psychedelic drug programs 1 2 3 . Vouchers awarded for: Compass' COMP360 psilocybin for treatment-resistant depression (TRD), Usona's PSIL201 psilocybin for major depressive disorder (MDD), and Transcend's TSND-201 methylone for PTSD 2 3 4 . This follows President Trump's April 18 executive order to accelerate psychedelic mental health treatments; CNPVs shorten NDA review from 10-12 months to 1-2 months 1 2 3 . All recipients have prior FDA Breakthrough Therapy Designations; Compass confirmed receipt and rolling review approval, with positive Phase 3 data for COMP360 1 2 6 . Announcement made April 24/25, 2026; FDA did not initially name recipients, but companies confirmed 1 4 5 . Sources: 1. https://pharmaphorum.com/news/fda-grants-three-priority-vouchers-psychedelics 2. https://...